All In Biotech

Drug Trial Radar · NCT07926321

A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

A Randomised, Double-blind, Placebo-controlled Phase IIa Trial to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BI 3810477 With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Nov 13, 2026

Primary completion

Jan 27, 2028

Study completion Apr 20, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for adults aged 40 and older who have idiopathic pulmonary fibrosis (IPF). Women can only participate if they cannot get pregnant. The purpose of this study is to find out whether a medicine called BI 3810477 can slow down the worsening of lung function in people with IPF. Participants are put into 2 groups randomly, which means by chance. One group receives BI 3810477 and the other group receives placebo. Placebo looks like BI 3810477 but does not contain any medicine. Participants receive BI 3810477 or placebo for 12 weeks. Participants may continue their regular treatment for IPF during the study. Participants are in the study for about 6 to 7 months. During this time, they visit the study site regularly, about 18 times. Some of the visits may be done at the participant's home instead of the study site. Doctors regularly test how well the lungs work by doing lung function tests. They also look at lung scans and measure markers in the blood that are linked to lung health. The results are compared between the 2 groups to see whether BI 3810477 works. The doctors also regularly check participants' health and note any unwanted effects.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • PlaceboOther

    Placebo

  • BI 3810477Biological

    BI 3810477

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in forced vital capacity (FVC) [mL] at Week 12Time frame: At baseline and at Week 12.

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Arizona

    Tucson, Arizona

  • Newport Native MD, Inc

    Newport Beach, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Avanza Medical Research Center

    Pensacola, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • Duke University Medical Center

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Baylor University Medical Center

    Dallas, Texas

  • University of Utah Health Sciences Center

    Salt Lake City, Utah

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium

  • Helsinki University Hospital

    Helsinki, Finland

  • Tampere University Hospital

    Tampere, Finland

  • Turku University Hospital / TYKS

    Turku, Finland

  • Universitätsklinikum Aachen, AöR

    Aachen, Germany

  • Vivantes Klinikum Neukölln

    Berlin, Germany

  • Caritas-Krankenhaus St. Maria gGmbH

    Donaustauf, Germany

  • Krankenhaus Bethanien gGmbH

    Solingen, Germany

  • Helios Hanseklinikum Stralsund

    Stralstund, Germany

  • University of Fukui Hospital

    Fukui, Yoshida-gun, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Fukuoka, Japan

  • Sapporo Medical University Hospital

    Hokkaido, Sapporo, Japan

  • Kanagawa Cardiovascular and Respiratory Center

    Kanagawa, Yokohama, Japan

  • Saiseikai Kumamoto Hospital

    Kumamoto, Kumamoto, Japan

  • National Hospital Organization Kinki-Chuo Chest Medical Center

    Osaka, Sakai, Japan

  • Hamamatsu University Hospital

    Shizuoka, Hamamatsu, Japan

  • Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas

    Distrito Federal, Mexico

  • Centro de Investigacion Farmacologica del Bajío, S.C.

    León, Mexico

  • Hospital Universitario Nuevo de Nuevo León - CEPREP

    Monterrey, Nuevo León, Mexico

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitari de Bellvitge

    L'Hospitalet Del LLobregat, Spain

  • Hospital Universitario De La Princesa

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Royal Devon and Exeter Hospital, Wonford

    Exeter, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.